Home
»
Press Room
»
Hemophilia Market Size To Reach $21.07 Billion By 2030

Hemophilia Market Size To Reach $21.07 Billion By 2030

June 2025 | Report Format: Electronic (PDF)

Hemophilia Market Growth & Trends

The global hemophilia market size is estimated to reach USD 21.07 billion by 2030, registering a CAGR of 6.91% from 2025 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin’s Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin’s Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

key Request a free sample copy or view report summary: Hemophilia Market Report

Hemophilia Market Report Highlights

The type A segment held the largest share of the hemophilia market in 2024, owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy.
Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2024, attributable to the specialized nature of the treatment required for the condition
By therapy, factor replacement therapy held the largest share of the hemophilia market in 2024, as it is the major form of treatment used in both prophylaxis and on-demand treatment.
North America was the largest revenue-generating region in the hemophilia market in 2024, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance.

Hemophilia Market Segmentation

Grand View Research has segmented the global hemophilia market based on type, treatment type, therapy, distribution channel, and region:

Hemophilia Type Outlook (Revenue, USD Million, 2018 - 2030)

Hemophilia A
Hemophilia B
Others

Hemophilia Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

On-demand
Cure
Prophylaxis

Hemophilia Therapy Outlook (Revenue, USD Million, 2018 - 2030)

Factor Replacement Therapy
- Plasma derived Factor Concentrates
  - Factor VIII
  - Factor IX
- Recombinant Factor Concentrates
  - Factor VIII
  - Factor VII
  - Factor IX
Desmopressin & Fibrin sealants
Gene Therapy & Monoclonal Antibodies